ClinicalTrials.gov
public full text
Public Domain
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this study population is to evaluate disease severity over time in participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index (HBI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease#969248
- Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease#1280208
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)#896070
- Early Prediction of Primary Non-Response to Infliximab in Crohn's Disease Using Routinely Available Clinical and Week 2 Laboratory Indicators: A Two-Center Real-World Cohort Study.#1107487
- Based on the Special Disease Management of Crohn's Disease Diet Studies#881409
Record · ID 1307722
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive